-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Search results for: “lectureship award”
-
EA5181 Confirms Durvalumab After CRT is SOC for Unresectable Stage III NSCLC
Dr. John Varlotto highlighted that the survival curves were ‘superimposable,’ showing no differences in median OS or PFS outcomes.
-
HypoRT with Concurrent Chemo Shows Favorable Safety Profile
Dr. Nan Bi said further investigation of HypoRT with immunotherapy is warranted based on these findings and potential immune-sparing benefits.
-
STAS is Associated with Poor Prognosis in Early-Stage NSCLC Regardless of Surgical Approach
JCOG0802/WJOG4607L data validate segmentectomy as non-inferior to lobectomy, regardless of the presence of STAS, Dr. Yasushi Yatabe said.
-
Novel Meta-Analysis Shows VATS Improves Overall Survival in Early-Stage Lung Cancer
Dr. Jacie Jiaqi Law shared results from a first-ever meta-analysis demonstrating that VATS reduces mortality risk without compromising disease-free survival.
-
Lessons from ECOG-ACRIN E4512: Could Limited Gains Lead to Positive Direction in Refining Adjuvant Therapy?
Discussant Dr. Jessica L. Lin said the results won’t change clinical practice after Dr. David Gerber reported no differences in OS or DFS.
-
Ivonescimab-Chemotherapy Combo Shows Promise as Post-TKI Option in EGFR-Mutant NSCLC
Dr. Jonathan W. Goldman reported that ivonescimab plus chemotherapy yielded a consistent PFS benefit across subgroups.
-
ARROS-1 Findings Reinforce Potential of Zidesamtinib in Pretreated ROS1-Altered NSCLC
The highly ROS1-selective TKI showed durable responses in previously treated patients with ROS1-altered NSCLC, according to data presented by Dr. Alexander E. Drilon.
-
Aumolertinib Plus Chemo Shows Modest PFS Gain Over Monotherapy for EGFR/TSG-Mutant NSCLC
Investigator Dr. Jie Wang presented results from the first-of-its-kind trial comparing combination therapy with monotherapy in this patient population.
-
Scientific Plenary to Spotlight Innovation and Empowering Future Oncologists
During the session, Drs. Arsela Prelaj, Victor Velculescu, and Lars Konge will address topics that promise to shape the future of thoracic oncology.
-
Second WCLC 2025 Presidential Symposium Will Cover Different Disciplines in Thoracic Oncology
In addition to recent developments in lung cancer care, attendees will hear from outgoing IASLC President Dr. Paul Van Schil and incoming President Dr. Caicun Zhou.
View ILCN Archives
Provider Resources
Popular Articles